One pot synthesis of novel α,β-dichloro-β-trifluoromethylated enones and their application to the synthesis of trifluoromethylated heterocycles
摘要:
Trifluoropropynyllithium was reacted with 1 equiv of Weinreb benzamides in THF at -78 to 0 degrees C followed by treatment with 4 equiv of trifluoromethanesulfonyl chloride to give alpha,beta-dichloro-beta-trifluoromethylated enones 1 in 61-68% yield. The reactions of 1a with substituted amidines or hydrazines in refluxing 1,4-dioxane-CH3CN afforded trifluoromethylated chloropyrimidines 3 and chloropyrazoles 6 in 58-98% yields. The microwave-assisted coupling reactions of 3 with substituted phenylstannane and allylstannane in refluxing CH3CN in the presence of Pd(PPh3)(4) provided the corresponding phenyl and allyl substituted pyrimidines 4 in 89-98% yields. (c) 2006 Published by Elsevier B.V.
[EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS<br/>[FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES
申请人:CHEMOCENTRYX INC
公开号:WO2003105853A1
公开(公告)日:2003-12-24
Compounds are provided that act as potent antagonists of the CCR1 receptor, and which
have been further confirmed in animal testing for inflammation, one of the hallmark
disease states for CCR1. The compounds are generally aryl piperazine derivatives
and are useful in pharmaceutical compositions, methods for the treatment of
CCR1-mediated diseases, and as controls in assays for the identification of
competitive CCR1 antagonists.
Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Electrophilic halogenation is used to produce a wide variety of halogenated compounds. Previously reported methods have been developed mainly using a reagent‐based approach. Unfortunately, a suitable “catalytic” process for halogen transfer reactions has yet to be achieved. In this study, arylamines have been found to generate an N‐halo arylamine intermediate, which acts as a highly reactive but selective catalytic
Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
[EN] 2-(PYRAZOL-5-YL-OXYMETHYL)-1,2-BENZISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] 1,1-DIOXYDES DE 2-(PYRAZOL-5-YL-OXYMETHYL)-1,2-BENZOTHIAZOL-3(2H)-ONE ET COMPOSITIONS PHARMACEUTIQUE LES CONTENANT
申请人:SANOFI
公开号:WO1997010243A1
公开(公告)日:1997-03-20
(EN) 2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides of formula (I), pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.(FR) La présente invention concerne des 1,1-dioxydes de 2-(pyrazol-5-yl-oxyméthyl)-1,2-benzothiazol-3(2H)-one représentés par la formule (I). L'invention concerne également des compositions pharmaceutiques les contenant et des procédés de traitement d'affections dégénératives dans lesquels ces compostions pharmaceutiques sont utilisées.